These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 24366366)

  • 1. Competitive bidding for Medicare Part B clinical laboratory services.
    Kautter J; Pope GC
    Int J Health Care Finance Econ; 2014 Jun; 14(2):95-108. PubMed ID: 24366366
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Medicare Program; End-Stage Renal Disease Prospective Payment System, Coverage and Payment for Renal Dialysis Services Furnished to Individuals With Acute Kidney Injury, End-Stage Renal Disease Quality Incentive Program, Durable Medical Equipment, Prosthetics, Orthotics and Supplies Competitive Bidding Program Bid Surety Bonds, State Licensure and Appeals Process for Breach of Contract Actions, Durable Medical Equipment, Prosthetics, Orthotics and Supplies Competitive Bidding Program and Fee Schedule Adjustments, Access to Care Issues for Durable Medical Equipment; and the Comprehensive End-Stage Renal Disease Care Model. Final rule.
    Centers for Medicare & Medicaid Services (CMS), HHS
    Fed Regist; 2016 Nov; 81(214):77834-969. PubMed ID: 27905888
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Medicare program; payment policies under the physician fee schedule and other revisions to Part B for CY 2011. Final rule with comment period.
    Centers for Medicare & Medicaid Services (CMS), HHS
    Fed Regist; 2010 Nov; 75(228):73169-860. PubMed ID: 21121181
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Medicare's demonstration of competitive bidding for clinical laboratory services: what it means for clinical laboratories.
    Hoerger TJ; Lindrooth RC; Eggleston JL
    Clin Chem; 1998 Aug; 44(8 Pt 1):1728-34. PubMed ID: 9702960
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Medicare Program; End-Stage Renal Disease Prospective Payment System, Payment for Renal Dialysis Services Furnished to Individuals With Acute Kidney Injury, End-Stage Renal Disease Quality Incentive Program, Durable Medical Equipment, Prosthetics, Orthotics and Supplies (DMEPOS) Competitive Bidding Program (CBP) and Fee Schedule Amounts, and Technical Amendments To Correct Existing Regulations Related to the CBP for Certain DMEPOS. Final rule.
    Centers for Medicare & Medicaid Services (CMS), HHS
    Fed Regist; 2018 Nov; 83(220):56922-7073. PubMed ID: 30457290
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Competitive bidding for Medicare services.
    Hoerger TJ; Waters TM
    Med Care; 1993 Oct; 31(10):879-97. PubMed ID: 8412391
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The national market for Medicare clinical laboratory testing: implications for payment reform.
    Gass Kandilov AM; Pope GC; Kautter J; Healy D
    Medicare Medicaid Res Rev; 2012; 2(2):. PubMed ID: 24800143
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Medicare program; competitive acquisition for certain durable medical equipment, prosthetics, orthotics, and supplies (DMEPOS) and other issues. Final rule.
    Centers for Medicare & Medicaid Services (CMS), HHS
    Fed Regist; 2007 Apr; 72(68):17991-8090. PubMed ID: 17520756
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Competitive bidding: an update.
    Comeaux L; Davis J; Lavanty D
    Clin Lab Sci; 2007; 20(2):66-8. PubMed ID: 17557703
    [No Abstract]   [Full Text] [Related]  

  • 10. Competitive bidding in Medicare Advantage: effect of benchmark changes on plan bids.
    Song Z; Landrum MB; Chernew ME
    J Health Econ; 2013 Dec; 32(6):1301-12. PubMed ID: 24308881
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Medicare program; revisions to payment policies under the physician fee schedule for calendar year 2006 and certain provisions related to the Competitive Acquisitions Program of outpatient drugs and biologicals under Part B. Final rule with comment.
    Centers for Medicare & Medicaid Services (CMS), HHS
    Fed Regist; 2005 Nov; 70(223):70115-476. PubMed ID: 16299947
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Medicare program; competitive acquisition of outpatient drugs and biologicals under Part B. Interim final rule with comment period.
    Centers for Medicare & Medicaid Services (CMS), HHS
    Fed Regist; 2005 Jul; 70(128):39021-102. PubMed ID: 15999432
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Physician payment reform: past and future.
    Epstein AM; Blumenthal D
    Milbank Q; 1993; 71(2):193-215. PubMed ID: 8510600
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Medicare program; revisions to payment policies under the physician fee schedule, and other Part B payment policies for CY 2008; revisions to the payment policies of ambulance services under the ambulance fee schedule for CY 2008; and the amendment of the e-prescribing exemption for computer generated facsimile transmissions. Final rule with comment period.
    Centers for Medicare & Medicaid Services (CMS), HHS
    Fed Regist; 2007 Nov; 72(227):66221-578. PubMed ID: 18044032
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improving the design of competitive bidding in Medicare Advantage.
    Cawley JH; Whitford AB
    J Health Polit Policy Law; 2007 Apr; 32(2):317-47. PubMed ID: 17463410
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Medicare outpatient clinical laboratory services payments: relative value scale approach.
    Gurny PA; Clopton TA
    Health Care Financ Rev; 1986; 8(2):45-52. PubMed ID: 10317880
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Laboratory reimbursement--competitive bidding and after.
    Davis J
    Clin Lab Sci; 2008; 21(4):194-5. PubMed ID: 19174976
    [No Abstract]   [Full Text] [Related]  

  • 18. The notice of proposed rule making for the new Medicare physician payment system: AMA summary and analysis.
    Ala Med; 1991 Jun; Suppl():1-60. PubMed ID: 1887827
    [No Abstract]   [Full Text] [Related]  

  • 19. Medicare program; fee schedule for physicians' services--HCFA. Correction of final rule.
    Fed Regist; 1992 Sep; 57(179):42491-510. PubMed ID: 10121910
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The new laboratory compendium by the KBV carries a significant regress potential].
    MMW Fortschr Med; 2014 Mar; 156 Spec No 1(1):12. PubMed ID: 24930333
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.